CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 22-204

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

Department of Health and Human Services Food and Drug Administration		Form Approved: OMB No. 0910-0513 Expiration Date: 04/30/10		
PATENT INFORMATION SUBMITTED WITH THE			See OMB Statement on Page 3. NDA NUMBER	
FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT		22,204		
For Each Patent That Claims a D	rug Subs	tance	NAME OF APPLICANT / NDA HOLDER	
(Active Ingredient), Drug Product (Formulat	ion and	Watson Laboratories, Inc.	
Composition) and/or Metho	od of Use			
The following is provided in accordance with	Section 50	5(b) and (c) of the Fo	ederal Food, Drug, and Cosmetic Act.	
TRADE NAME (OR PROPOSED TRADE NAME) Oxybutynin Chloride Topical Gel				
ACTIVE INGREDIENT(S)		STRENGTH(S)		
Oxybutynin		100mg/gram		
DOSAGE FORM				
Topical Gel			•	
This patent declaration form is required to be subm amendment, or supplement as required by 21 CFR 314.53	litted to the at the addres	e Food and Drug A ss provided in 21 CFR	dministration (FDA) with an NDA application, 314.53(d)(4).	
Within thirty (30) days after approval of an NDA or su	pplement, or	within thirty (30) da	ys of issuance of a new patent, a new patent	
declaration must be submitted pursuant to 21 CFR 3 or supplement. The information submitted in the declar	14.53(c)(2)(ii)) with all of the required upon or of	lired information based on the approved NDA	
upon by FDA for listing a patent in the Orange Book.		submitted upon of al		
For hand-written or typewriter versions (only) of t	his report:	If additional space i	s required for any narrative answer (i.e., one	
that does not require a "Yes" or "No" response), please	attach an ac	ditional page referen	cing the question number.	
FDA will not list patent information if you file an patent is not eligible for listing.	n Incomple	te patent declarati	on or the patent declaration indicates the	
For each patent submitted for the pending NDA,	amendmer	nt. or supplement r	eferenced above, you must submit all the	
information described below. If you are not subl	mitting any	patents for this p	pending NDA, amendment, or supplement,	
complete above section and sections 5 and 6.				
1. GENERAL		•.		
a. United States Patent Number 7,179,483		ate of Patent ry 20, 2007	c. Expiration Date of Patent April 26, 2020	
d. Name of Patent Owner		Patent Owner)		
Watson Pharmaceuticals, Inc.	311 Bonnie	Circle		
	City/State	·····	· · · · · · · · · · · · · · · · · · ·	
	Corona, CA	Å		
	ZIP Code	·····	FAX Number (if available)	
· · ·	92880			
	Telephone	Number	E-Mail Address (if available)	
	951-493-59			
e. Name of agent or representative who resides or maintains	Address (or	f agent or representative	named in 1 e)	
a place of business within the United States authorized to		agent of representative		
receive notice of patent certification under section				
505(b)(3) and (j)(2)(B) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.52 and 314.95 (if patent City/State				
owner or NDA applicant/holder does not reside or have a				
place of business within the United States)	ZIP Code		FAX Number (if available)	
	Telephone	Number	E-Mail Address (if available)	
f. Is the patent referenced above a patent that has been subm	l	sly for the		
approved NDA or supplement referenced above?			Yes No	
g. If the patent referenced above has been submitted previous	sly for listing, i	is the expiration		
date a new expiration date?			🗌 Yes 🛛 No	

FORM FDA 3542a (7/07)

-

For use	For the patent referenced above, provide the following information on the drug substance, drug product and/or method of use that is the subject of the pending NDA, amendment, or supplement.				
2. [Prug Substance (Active Ingredient)				
2.1	Does the patent claim the drug substance that is the active ingredient in the drug product described in the pending NDA, amendment, or supplement?	Yes	No No		
2.2	Does the patent claim a drug substance that is a different polymorph of the active ingredient described in the pending NDA, amendment, or supplement?	Yes	No		
2.3	If the answer to question 2.2 is "Yes," do you certify that, as of the date of this declaration, you have test data demonstrating that a drug product containing the polymorph will perform the same as the drug product described in the NDA? The type of test data required is described at 21 CFR 314.53(b).	Yes	No		
2,4	Specify the polymorphic form(s) claimed by the patent for which you have the test results described in 2.3.	s	· · · · · · · · · · · · · · · · · · ·		
2.5	Does the patent claim only a metabolite of the active ingredient pending in the NDA or supplement? (Complete the information in section 4 below if the patent claims a pending method of using the pending drug product to administer the metabolite.)	Yes	🖾 No		
2.6	Does the patent claim only an intermediate?	Yes	No		
2.7	If the patent referenced in 2.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)	Yes	No		
3. E	Prug Product (Composition/Formulation)				
3.1	Does the patent claim the drug product, as defined in 21 CFR 314.3, in the pending NDA, amendment, or supplement?	Yes	No No		
3.2	Does the patent claim only an intermediate?	Yes	No No		
3.3	If the patent referenced in 3.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)	Yes	No No		
4. N	Aethod of Use				
Sponsors must submit the information in section 4 for each method of using the pending drug product for which approval is being sought that is claimed by the patent. For each pending method of use claimed by the patent, provide the following information:					
4.1	Does the patent claim one or more methods of use for which approval is being sought in the pending NDA, amendment, or supplement?	🛛 Yes	No		
4.2 1	Patent Claim Number(s) (as listed in the patent) Does (Do) the patent claim(s) referenced in 4.2 claim a pending method of use for which approval is being soug in the pending NDA, amendment, or supplement?	ht 🛛 Yes	🗌 No		
4.2a	If the answer to 4.2 is Use: (Submit indication or method of use information as identified specifically in TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH FREQUENCY, URGENCY, OR URGE INCONTINENCE Isolating for the drug product. Intre pending NDA, antenantent, of supplement?	the approved lab	eling.)		
5. N	to Relevant Patents		•		
drug vhia	this pending NDA, amendment, or supplement, there are no relevant patents that claim the drug substance (are product (formulation or composition) or method(s) of use, for which the applicant is seeking approval and with the a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent manufacture, use, or sale of the drug product.	n respect to	Yes		

Department of Health and Human Services Food and Drug Administration PATENT INFORMATION SUBMITTED WITH THE FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT For Each Patent That Claims a Drug Substance (Active Ingredient), Drug Product (Formulation and Composition) and/or Method of Use		Form Approved: OMB No. 0910-0513 Expiration Date: 04/30/10 See OMB Statement on Page 3. NDA NUMBER		
		22,204 NAME OF APPLICANT / NDA HOLDER Watson Laboratories, Inc.		
The following is provided in accordance with TRADE NAME (OR PROPOSED TRADE NAME)	Section 50	5(b) and (c) of the Fe	ederal Food, Drug, and Cosmetic Act.	
Oxybutynin Chloride Topical Gel				
ACTIVE INGREDIENT(S) Oxybutynin		STRENGTH(S) 100 mg/gram		
DOSAGE FORM Topical Gel		L,,,,		
This patent declaration form is required to be submared amendment, or supplement as required by 21 CFR 314.53 Within thirty (30) days after approval of an NDA or suddeclaration must be submitted pursuant to 21 CFR 31 or supplement. The information submitted in the declar upon by FDA for listing a patent in the Orange Book.	at the addres pplement, or 14.53(c)(2)(ii)	s provided in 21 CFR within thirty (30) da with all of the requ	314.53(d)(4). ys of issuance of a new patent, a new patent lired information based on the approved NDA	
For hand-written or typewriter versions (only) of this report: If additional space is required for any narrative answer (i.e., one that does not require a "Yes" or "No" response), please attach an additional page referencing the question number.				
FDA will not list patent information if you file an patent is not eligible for listing.	n incomple	te patent declaratio	on or the patent declaration indicates the	
For each patent submitted for the pending NDA, information described below. If you are not sub- complete above section and sections 5 and 6.				
1. GENERAL a. United States Patent Number	b issue Da	ate of Patent	c. Expiration Date of Patent	
7,029,694	April 18		April 26, 2020	
d. Name of Patent Owner Watson Laboratories, Inc	Address (of 577 Chipeta	Patent Owner) a Way		
	City/State Salt Lake C	City, UT		
	ZIP Code 84108		FAX Number (<i>if availabl</i> e)	
	Telephone I 951-493-53		E-Mail Address (if available)	
e. <u>Name of agent or representative</u> who resides or maintains a place of business within the United States authorized to receive notice of patent certification under section 505(b)(3) and (j)(2)(B) of the Federal Food, Drug, and	Address (of	agent or representative	named in 1.e.)	
Cosmetic Act and 21 CFR 314.52 and 314.95 (if patent owner or NDA applicant/holder does not reside or have a place of business within the United States)		City/State		
Ċ.	ZIP Code		FAX Number (if available)	
	Telephone	Number	E-Mail Address (if available)	
f. Is the patent referenced above a patent that has been submapproved NDA or supplement referenced above?			Yes No	
g. If the patent referenced above has been submitted previous date a new expiration date?	ily for listing, i	s the expiration	🗌 Yes 🛛 No	

For use	the patent referenced that is the subject of th	above, provide the following information on the drug substance, e pending NDA, amendment, or supplement.	drug produci	and/or method of
2. C	Orug Substance (Active I	ngredient)		
2.1 		rug substance that is the active ingredient in the drug product DA, amendment, or supplement?] Yes	No No
2.2		g substance that is a different polymorph of the active pending NDA, amendment, or supplement?	Yes	No No
2.3	demonstrating that a drug p	2 is "Yes," do you certify that, as of the date of this declaration, you have test date roduct containing the polymorph will perform the same as the drug product	_	No
	·	type of test data required is described at 21 CFR 314.53(b).	U Yes	
2.4	Зреску ше рокулогранстоя	m(s) claimed by the patent for which you have the test results described in 2.3.		
2.5		a metabolite of the active ingredient pending in the NDA or supplement? In section 4 below if the patent claims a pending method of using the pending he metabolite.)	Yes	No
2.6	Does the patent claim only	an intermediate?	Yes	No
2.7		.1 is a product-by-process patent, is the product claimed in the s required only if the patent is a product-by-process patent.)	Yes	🗌 No
3. [Drug Product (Compositi	ion/Formulation)		
3.1	Does the patent claim the d amendment, or supplement	rug product, as defined in 21 CFR 314.3, in the pending NDA, ?	X Yes	No
3.2	Does the patent claim only	an intermediate?	Yes	No
3.3	-	.1 is a product-by-process patent, is the product claimed in the		
	patent novel? (An answer is	s required only if the patent is a product-by-process patent.)	Yes	L No
4. N	lethod of Use			
Sponsors must submit the information in section 4 for each method of using the pending drug product for which approval is being sought that is claimed by the patent. For each pending method of use claimed by the patent, provide the following information:				
4.1	Does the patent claim one of the pending NDA, amendm	or more methods of use for which approval is being sought in ent_or supplement?	🛛 Yes	No
4.2	Patent Claim Number(s) (as			
		in the pending NDA, amendment, or supplement?	Yes	No
4.2a	If the answer to 4.2 is "Yes," identify with speci- ficity the use with refer- ence to the proposed labeling for the drug product.	Use: (Submit Indication or method of use information as identified specifically in TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WIT FREQUENCY, URGENCY, OR URGE INCONTINENCE		
5. 1	No Relevant Patents			
drug vhia	product (formulation or com	ent, or supplement, there are no relevant patents that claim the drug substance (a position) or method(s) of use, for which the applicant is seeking approval and wi nent could reasonably be asserted if a person not licensed by the owner of the pathe drug product.	th respect to	, Yes

,

6. Declaration Certification			
6.1 The undersigned declares that this is an accur amendment, or supplement pending under sec sensitive patent information is submitted purs this submission complies with the requirement is true and correct.	ction 505 of the F uant to 21 CFR 3	ederal Food, Drug, and C 14.53. I attest that I am fa	Cosmetic Act. This time- miliar with 21 CFR 314.53 and
Warning: A willfully and knowingly false stater	ment is a crimina	i offense under 18 U.S.C.	1001.
6.2 Authorized Signature of NDA Applicant/Holder or Patent other Authorized Official) (Provide Information below)	t Owner (Attorney, A	gent, Representative or	Date Signed
NOTE: Only an NDA applicant/holder may submit this holder is authorized to sign the declaration but may not s			
Check applicable box and provide information below.			
NDA Applicant/Holder		Applicant's/Holder's Attorney orized Official	, Agent (Representative) or other
Patent Owner	Pate Offic		epresentative) or Other Authorized
Name Watson Laboratories, Inc.		<u>.</u>	
Address 577 Chipeta Way		City/State Salt Lake City, Utah	
ZIP Code 84108		Telephone Number (801) 588-6324	
FAX Number (<i>if available</i>) (801) 588-6232		E-Mail Address (if available) kevin.barber@watson.com	
C 50	needed, and completin	ng and reviewing the collection o ns for reducing this burden to:	ing the time for reviewing instructions, f information. Send comments regarding this
An agency may not conduct or s information unles	sponsor, and a person is it displays a current	is not required to respond to, a c ly valid OMB control number.	ollection of

EXCLUSIVITY SUMMARY

NDA # 22-204

SUPPL #

HFD # 580

Trade Name Gelnique

Generic Name oxybutynin chloride 10% topical gel

Applicant Name Watson Laboratories, Inc.

Approval Date, If Known January 27, 2009

PART I IS AN EXCLUSIVITY DETERMINATION NEEDED?

1. An exclusivity determination will be made for all original applications, and all efficacy supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following questions about the submission.

a) Is it a 505(b)(1), 505(b)(2) or efficacy supplement?

YES 🖂	NO

If yes, what type? Specify 505(b)(1), 505(b)(2), SE1, SE2, SE3, SE4, SE5, SE6, SE7, SE8

505(b)(1)

c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "no.")

YES 🖂	NO
-------	----

If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study.

If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data:

d) Did the applicant request exclusivity?

YES 🛛 NO 🗌

If the answer to (d) is "yes," how many years of exclusivity did the applicant request?

3 Years

e) Has pediatric exclusivity been granted for this Active Moiety? YES 🕅

NO 🗌

If the answer to the above question in YES, is this approval a result of the studies submitted in response to the Pediatric Written Request?

No

IF YOU HAVE ANSWERED "NO" TO <u>ALL</u> OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS AT THE END OF THIS DOCUMENT.

2. Is this drug product or indication a DESI upgrade?

YES NO	О 🖂
--------	-----

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8 (even if a study was required for the upgrade).

PART II FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES

(Answer either #1 or #2 as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.



If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA#	21-351	Oxytrol (oxybutynin transdermal system)
NDA#	20-897	Ditropan XL (oxybutynin chloride) Tablets
NDA#	17-577	Ditropan (oxybutynin chloride) Tablets

2. <u>Combination product</u>.

If the product contains more than one active moiety(as defined in Part II, #1), has FDA previously approved an application under section 505 containing <u>any one</u> of the active moieties in the drug product? If, for example, the combination contains one never-before-approved active moiety and one previously approved active moiety, answer "yes." (An active moiety that is marketed under an OTC monograph, but that was never approved under an NDA, is considered not previously approved.)

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA#

NDA#

NDA#

IF THE ANSWER TO QUESTION 1 OR 2 UNDER PART II IS "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8. (Caution: The questions in part II of the summary should only be answered "NO" for original approvals of new molecular entities.) IF "YES," GO TO PART III.

PART III THREE-YEAR EXCLUSIVITY FOR NDAs AND SUPPLEMENTS

To qualify for three years of exclusivity, an application or supplement must contain "reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant." This section should be completed only if the answer to PART II, Question 1 or 2 was "yes."

1. Does the application contain reports of clinical investigations? (The Agency interprets "clinical investigations" to mean investigations conducted on humans other than bioavailability studies.) If the application contains clinical investigations only by virtue of a right of reference to clinical investigations in another application, answer "yes," then skip to question 3(a). If the answer to 3(a) is "yes" for any investigation referred to in another application, do not complete remainder of

summary for that investigation.

VEC	\sim	NO
IES	\square	NU

IF "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. A clinical investigation is "essential to the approval" if the Agency could not have approved the application or supplement without relying on that investigation. Thus, the investigation is not essential to the approval if 1) no clinical investigation is necessary to support the supplement or application in light of previously approved applications (i.e., information other than clinical trials, such as bioavailability data, would be sufficient to provide a basis for approval as an ANDA or 505(b)(2) application because of what is already known about a previously approved product), or 2) there are published reports of studies (other than those conducted or sponsored by the applicant) or other publicly available data that independently would have been sufficient to support approval of the application, without reference to the clinical investigation submitted in the application.

(a) In light of previously approved applications, is a clinical investigation (either conducted by the applicant or available from some other source, including the published literature) necessary to support approval of the application or supplement?

YES 🖂	NO [
-------	------	--

If "no," state the basis for your conclusion that a clinical trial is not necessary for approval AND GO DIRECTLY TO SIGNATURE BLOCK ON PAGE 8:

(b) Did the applicant submit a list of published studies relevant to the safety and effectiveness of this drug product and a statement that the publicly available data would not independently support approval of the application?

YES		NO	imes
-----	--	----	------

(1) If the answer to 2(b) is "yes," do you personally know of any reason to disagree with the applicant's conclusion? If not applicable, answer NO.



If yes, explain:

(2) If the answer to 2(b) is "no," are you aware of published studies not conducted or sponsored by the applicant or other publicly available data that could independently demonstrate the safety and effectiveness of this drug product?



If yes, explain:

(c) If the answers to (b)(1) and (b)(2) were both "no," identify the clinical investigations submitted in the application that are essential to the approval:

Study OG05009

Studies comparing two products with the same ingredient(s) are considered to be bioavailability studies for the purpose of this section.

3. In addition to being essential, investigations must be "new" to support exclusivity. The agency interprets "new clinical investigation" to mean an investigation that 1) has not been relied on by the agency to demonstrate the effectiveness of a previously approved drug for any indication and 2) does not duplicate the results of another investigation that was relied on by the agency to demonstrate the effectiveness of a previously approved drug product, i.e., does not redemonstrate something the agency considers to have been demonstrated in an already approved application.

a) For each investigation identified as "essential to the approval," has the investigation been relied on by the agency to demonstrate the effectiveness of a previously approved drug product? (If the investigation was relied on only to support the safety of a previously approved drug, answer "no.")

Investigation #1	YES	NO 🖂
Investigation #2	YES	NO 🗌

If you have answered "yes" for one or more investigations, identify each such investigation and the NDA in which each was relied upon:

b) For each investigation identified as "essential to the approval", does the investigation duplicate the results of another investigation that was relied on by the agency to support the effectiveness of a previously approved drug product?

Investigation #1	YES 🗌	NO 🖂
Investigation #2	YES 🗌	NO 🗌


If you have answered "yes" for one or more investigation, identify the NDA in which a similar investigation was relied on:

c) If the answers to 3(a) and 3(b) are no, identify each "new" investigation in the application or supplement that is essential to the approval (i.e., the investigations listed in #2(c), less any that are not "new"):

Study OG05009

4. To be eligible for exclusivity, a new investigation that is essential to approval must also have been conducted or sponsored by the applicant. An investigation was "conducted or sponsored by" the applicant if, before or during the conduct of the investigation, 1) the applicant was the sponsor of the IND named in the form FDA 1571 filed with the Agency, or 2) the applicant (or its predecessor in interest) provided substantial support for the study. Ordinarily, substantial support will mean providing 50 percent or more of the cost of the study.

a) For each investigation identified in response to question 3(c): if the investigation was carried out under an IND, was the applicant identified on the FDA 1571 as the sponsor?



(b) For each investigation not carried out under an IND or for which the applicant was not identified as the sponsor, did the applicant certify that it or the applicant's predecessor in interest provided substantial support for the study?

Investigation #1	!
YES Explain:	! NO ! Explain:
Investigation #2	!
YES Explain:	! NO

(c) Notwithstanding an answer of "yes" to (a) or (b), are there other reasons to believe that the applicant should not be credited with having "conducted or sponsored" the study? (Purchased studies may not be used as the basis for exclusivity. However, if all rights to the drug are purchased (not just studies on the drug), the applicant may be considered to have sponsored or conducted the studies sponsored or conducted by its predecessor in interest.)



If yes, explain:

Name of person completing form: Jeannie Roule Title: Regulatory Health Project Manager Date: January 26, 2009

Name of Office/Division Director signing form: George Benson, M.D. Title: Deputy Director

Form OGD-011347; Revised 05/10/2004; formatted 2/15/05

/s/

George Benson 1/27/2009 01:50:58 PM

(Con	nplete for all f	PEDIATRIC iled original application	,	efficacy supplements)	
NDA/BLA#: <u>22-204</u>		Supplement Number	r:	NDA Supplement Type (e.g. SE5):	
Division Name:		PDUFA Goal Date: 1	1/27/09	Stamp Date: <u>3/27/2008</u>	
Division of Reproductive Urologic Products	e and				
Proprietary Name: <u>G</u>	<u> Selnique</u>				
Established/Generic Na	me: <u>Oxybuty</u>	nin Chloride 10% gel	l		
Dosage Form: <u>gel</u>					
Applicant/Sponsor: <u>V</u>	Vatson Labora	tories			
Indication(s) <u>previously</u> (1) (2) (3) (4)	<u>approved</u> (ple	ase complete this que	estion for s	supplements and Type 6 NDAs only):	
Pediatric use for each p application under review	oediatric subpo w. A Pediatric	pulation must be add Page must be compl	lressed for eted for ea	each indication covered by current indication.	
Number of indications f (Attach a completed Pe			urrent app	lication.)	
Indication: Overactive frequency.	Bladder (OA	B)with symptoms of	urge urin	ary incontinence, urgency, and	
Q1: Is this application in	n response to a	a PREA PMR?	Yes 🗌 C	continue	
			No 🛛 P	lease proceed to Question 2.	
If Yes, NDA/BL/	\#:	Supplement #	t:	PMR #:	
		nis is a complete resp	onse to the	e PMR?	
	•	ed to Section D.			
	•			ne Pediatric Page, as applicable.	
question):				ies that apply and proceed to the next	
(a) NEW active ingr regimen; or route of			n); 🗌 indic	ation(s); 🛛 dosage form; 🗌 dosing	
(b) 🗌 No. PREA does	not apply. Ski	p to signature block	ζ.		
* Note for CDER: SE5	, SE6, and SE	7 submissions may	also trigg	er PREA.	
Q3: Does this indication	n have orphan	designation?			
🗌 Yes. PREA	does not apply	/. Skip to signature	block.		
🛛 No. Please	proceed to the	next question.	·		

Q4: Is there a full waiver for all pediatric age groups for this indication (check one)?

- Yes: (Complete Section A.)
- No: Please check all that apply:
 - Partial Waiver for selected pediatric subpopulations (Complete Sections B)
 - Deferred for some or all pediatric subpopulations (Complete Sections C)

Completed for some or all pediatric subpopulations (Complete Sections D)

Appropriately Labeled for some or all pediatric subpopulations (Complete Sections E)

Extrapolation in One or More Pediatric Age Groups (Complete Section F)

(Please note that Section F may be used alone or in addition to Sections C, D, and/or E.)

Section A: Fully Waived Studies (for all pediatric age groups)

Reason(s) for full waiver: (check, and attach a brief justification for the reason(s) selected)

Necessary studies would be impossible or highly impracticable because:

Disease/condition does not exist in children

Too few children with disease/condition to study

Other (e.g., patients geographically dispersed):

- Product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients AND is not likely to be used in a substantial number of pediatric patients.
- Evidence strongly suggests that product would be unsafe in all pediatric subpopulations (*Note: if studies are fully waived on this ground, this information must be included in the labeling.*)
- Evidence strongly suggests that product would be ineffective in all pediatric subpopulations (*Note: if studies are fully waived on this ground, this information must be included in the labeling.*)
- Evidence strongly suggests that product would be ineffective and unsafe in all pediatric subpopulations (*Note: if studies are fully waived on this ground, this information must be included in the labeling.*)
- Justification attached.

If studies are fully waived, then pediatric information is complete for this indication. If there is another indication, please complete another Pediatric Page for each indication. Otherwise, this Pediatric Page is complete and should be signed.

Section B: Partially Waived Studies (for selected pediatric subpopulations)

Check subpopulation(s) and reason for which studies are being partially waived (fill in applicable criteria below): *Note: If Neonate includes premature infants, list minimum and maximum age in "gestational age" (in weeks).*

				Reason (see below for further detail):				
4		minimum	maximum	Not feasible [#]	Not meaningful therapeutic benefit*	Ineffective or unsafe [†]	Formulation failed ^{Δ}	
	Neonate	wk mo.	wk mo.					
\boxtimes	Other	<u>0</u> yr. <u>0</u> mo.	<u>5</u> yr. <u>11</u> mo.	\square				
	Other	yr mo.	yr mo.					
	Other	yr mo.	yr mo.					
	Other	yr mo.	yr mo.					

Are the indicated age ranges (above) based on weight (kg)?

Are the indicated age ranges (above) based on Tanner Stage?

Reason(s) for partial waiver (check reason corresponding to the category checked above, and attach a brief

IF THERE ARE QUESTIONS, PLEASE CONTACT THE CDER PMHS VIA EMAIL (cderpmhs@fda.hhs.gov) OR AT 301-796-0700.

justification):

- # Not feasible:
 - Necessary studies would be impossible or highly impracticable because:
 - Disease/condition does not exist in children
 - Too few children with disease/condition to study
 - Other (e.g., patients geographically dispersed): <u>The study endpoints are difficult to evaluate in</u> this age group.
- * Not meaningful therapeutic benefit:
 - Product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients in this/these pediatric subpopulation(s) AND is not likely to be used in a substantial number of pediatric patients in this/these pediatric subpopulation(s).
- † Ineffective or unsafe:
 - Evidence strongly suggests that product would be unsafe in all pediatric subpopulations (*Note: if studies are partially waived on this ground, this information must be included in the labeling.*)
 - Evidence strongly suggests that product would be ineffective in all pediatric subpopulations (*Note: if studies are partially waived on this ground, this information must be included in the labeling.*)
 - Evidence strongly suggests that product would be ineffective and unsafe in all pediatric subpopulations (*Note: if studies are partially waived on this ground, this information must be included in the labeling.*)
- Δ Formulation failed:
 - Applicant can demonstrate that reasonable attempts to produce a pediatric formulation necessary for this/these pediatric subpopulation(s) have failed. (*Note: A partial waiver on this ground may only cover the pediatric subpopulation(s) requiring that formulation. An applicant seeking a partial waiver on this ground must submit documentation detailing why a pediatric formulation cannot be developed. This submission will be posted on FDA's website if waiver is granted.*)

Justification attached.

For those pediatric subpopulations for which studies have not been waived, there must be (1) corresponding study plans that have been deferred (if so, proceed to Sections C and complete the PeRC Pediatric Plan Template); (2) submitted studies that have been completed (if so, proceed to Section D and complete the PeRC Pediatric Assessment form); (3) additional studies in other age groups that are not needed because the drug is appropriately labeled in one or more pediatric subpopulations (if so, proceed to Section E); and/or (4) additional studies in other age groups that are not needed because efficacy is being extrapolated (if so, proceed to Section F). Note that more than one of these options may apply for this indication to cover <u>all</u> of the pediatric subpopulations.

Section C: Deferred Studies (for selected pediatric subpopulations).

Check pediatric subpopulation(s) for which pediatric studies are being deferred (and fill in applicable reason below):

Deferrals (for each or all age groups):				Applicant Certification †				
Population minimum maximum		maximum	Ready for Approval in Adults	Need Additional Adult Safety or Efficacy Data	Other Appropriate Reason (specify below)*	Received		
	Neonate	wk mo.	wk mo.					
\boxtimes	Other	<u>6</u> yr. <u>0</u> mo.	<u>16</u> yr. <u>11</u> mo.	\square				
	Other	yr mo.	yr mo.					
	Other	yr mo.	yr mo.					
	Other	yr mo.	yr mo.					
	All Pediatric Populations	0 yr. 0 mo.	16 yr. 11 mo.	\boxtimes				
	Date studies are due (mm/dd/yy): <u>06/30/09 (Studies will begin)</u>							

Are the indicated age ranges (above) based on weight (kg)?

Are the indicated age ranges (above) based on Tanner Stage?

* Other Reason: <u>Justification: The sponsor requested a deferral for pediatric studies in children age 5 to 17</u> years old. The sponsor plans to first determine whether Oxytrol TDS is safe and effective in the pediatric population (Oxytrol Pediatric Study in pediatric patients with neurogenic bladder). If the results with Oxytrol are positive, the sponsor plans to discuss with the Division whether a pediatric study with OTG would be necessary. If the results of Oxytrol are negative, the sponsor may use these results to request a waiver for conducting pediatric studies in children age 5 to 17 years old.

No; Yes.

† Note: Studies may only be deferred if an <u>applicant submits a certification of grounds</u> for deferring the studies, a description of the planned or ongoing studies, evidence that the studies are being conducted or will be conducted with due diligence and at the earliest possible time, and a timeline for the completion of the studies. If studies are deferred, on an annual basis applicant must submit information detailing the progress made in conducting the studies or, if no progress has been made, evidence and documentation that such studies will be conducted with due diligence and at the earliest possible time. This requirement should be communicated to the applicant in an appropriate manner (e.g., in an approval letter that specifies a required study as a postmarketing commitment.)

If all of the pediatric subpopulations have been covered through partial waivers and deferrals, Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.

Population	minimum	maximum	PeRC Pediatric Assessment form attached?.		
Neonate	wk mo.	wk mo.	Yes 🗌	No 🗌	
Other	yr mo.	yr mo.	Yes 🗌	No 🗌	
Other	yr mo.	yr mo.	Yes 🗌	No 🗌	
Other	yr mo.	yr mo.	Yes 🗌	No 🗌	
Other	yr mo.	yr mo.	Yes 🗌	No 🗌	
All Pediatric Subpopulations	0 yr. 0 mo.	16 yr. 11 mo.	Yes 🗌	No 🗌	

Section D: Completed Studies (for some or all pediatric subpopulations).

No; Yes. Are the indicated age ranges (above) based on Tanner Stage?

Note: If there are no further pediatric subpopulations to cover based on partial waivers, deferrals and/or completed studies, Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.

Section E: Drug Appropriately Labeled (for some or all pediatric subpopulations):

Additional pediatric studies are not necessary in the following pediatric subpopulation(s) because product is appropriately labeled for the indication being reviewed:

Population		minimum	maximum
	Neonate	wk mo.	wk mo.
	Other	yr mo.	yr mo.
	Other	yr mo.	yr mo.
	Other	yr mo.	yr mo.
	Other	yr mo.	yr mo.
	All Pediatric Subpopulations	0 yr. 0 mo.	16 yr. 11 mo.

Are the indicated age ranges (above) based on weight (kg)?

□ No; □ Yes.

Are the indicated age ranges (above) based on Tanner Stage? No; Yes.

If all pediatric subpopulations have been covered based on partial waivers, deferrals, completed studies, and/or existing appropriate labeling, this Pediatric Page is complete and should be signed. If not, complete the rest of the Pediatric Page as applicable.

Section F: Extrapolation from Other Adult and/or Pediatric Studies (for deferred and/or completed studies)

Note: Pediatric efficacy can be extrapolated from adequate and well-controlled studies in adults and/or other pediatric subpopulations if (and only if) (1) the course of the disease/condition AND (2) the effects of the product are sufficiently similar between the reference population and the pediatric subpopulation for which information will be extrapolated. Extrapolation of efficacy from studies in adults and/or other children usually requires supplementation with other information obtained from the target pediatric subpopulation, such as

IF THERE ARE QUESTIONS, PLEASE CONTACT THE CDER PMHS VIA EMAIL (cderpmhs@fda.hhs.gov) OR AT 301-796-0700.

pharmacokinetic and safety studies. Under the statute, safety cannot be extrapolated.

Pediatric studies are not necessary in the following pediatric subpopulation(s) because efficacy can be extrapolated from adequate and well-controlled studies in adults and/or other pediatric subpopulations:						
Population				Extrapol	ated from:	
		minimum	maximum	Adult Studies?	Other Pediatric Studies?	
	Neonate	wk mo.	wk mo.			
	Other	yr mo.	yr mo.			
	Other	yr mo.	yr mo.			
	Other	yr mo.	yr mo.			
	Other	yr mo.	yr mo.			
	All Pediatric Subpopulations	0 yr. 0 mo.	16 yr. 11 mo.			

Are the indicated age ranges (above) based on weight (kg)?

□ No; □ Yes.

Note: If extrapolating data from either adult or pediatric studies, a description of the scientific data supporting the extrapolation must be included in any pertinent reviews for the application.

If there are additional indications, please complete the attachment for each one of those indications. Otherwise, this Pediatric Page is complete and should be signed and entered into DFS or DARRTS as appropriate after clearance by PeRC.

This page was completed by:

{See appended electronic signature page}

Regulatory Project Manager

(Revised: 6/2008)

NOTE: If you have no other indications for this application, you may delete the attachments from this document.

/s/ Jeannie Roule 1/28/2009 07:45:44 AM

1.3.3 DEBARMENT CERTIFICATION

Watson Laboratories, Inc. hereby certifies that it did not and will not use in any capacity the services of any person debarred under Sec. 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.

hair 1 A h

Susan Skara Senior Vice President Human Resources

ann

Kevin Barber, Ph.D., R.A.C., P.M.P. Executive Director Proprietary Regulatory Affairs

2-12-08 Date

14/2008 21 Date

ACTION PACKAGE CHECKLIST

APPLICATION INFORMATION ¹				
NDA # 22204 BLA #	NDA Supplement # BLA STN #		If NDA, Efficacy Suppleme	ent Type:
Established/Proper Nan			Applicant: Watson Laborat Agent for Applicant (if appl	
RPM: Jeannie Roule			Division: Division of Repr	oductive and Urologic Products
<u>NDAs</u> : NDA Application Type Efficacy Supplement:	$: \begin{tabular}{cccc} $505(b)(1) & 1 505(b)(2) \\ 1 505(b)(1) & 1 505(b)(2) \\ \end{tabular} \end{tabular} $	Liste	b)(2) Original NDAs and 505 d drug(s) referred to in 505(b /ANDA #(s) and drug name(s))(2) application (include
of whether the original Consult page 1 of the N	ither a (b)(1) or a (b)(2) regardless NDA was a (b)(1) or a (b)(2). IDA Regulatory Filing Review for endix A to this Action Package		ide a brief explanation of how l drug.	this product is different from the
			f no listed drug, check here a	nd explain:
		provi check exclu notif B of If per infor whet from On th	ided in Appendix B to the R king the Orange Book for an isivity. If there are any char y the OND ADRA immedia the Regulatory Filing Revie Dote of changes Date of check: diatric exclusivity has been mation in the labeling of the her pediatric information n the labeling of this drug.	Updated
 User Fee Goal Date Action Goal Date (•			January 27, 2009
✤ Actions				
Proposed action		AP TA AE NA CR		
Previous a	actions (specify type and date for each	h action	n taken)	🖾 None
Note: If accelerate within 120 days after the second secon			exceptions, see guidance	Received (N/A)

¹ The **Application Information** section is (only) a checklist. The **Contents of Action Package** section (beginning on page 5) lists the documents to be included in the Action Package.

*	Application ² Characteristics	
	Review priority: Standard Priority Chemical classification (new NDAs only):	
	Fast TrackRx-to-OTC full switchRolling ReviewRx-to-OTC partial switchOrphan drug designationDirect-to-OTC	
	Restricted distribution (21 CFR 314.520)Restricted Restricted Subpart HSubpart ISubpart H	rated approval (21 CFR 601.41) eted distribution (21 CFR 601.42) val based on animal studies
	 Submitted in response to a PMR Submitted in response to a PMC 	
	Comments:	
*	Date reviewed by PeRC (<i>required for approvals only</i>) If PeRC review not necessary, explain:	Review completed on January 15, 2009
*	BLAs only: <i>RMS-BLA Product Information Sheet for TBP</i> has been completed and forwarded to OBPS/DRM (<i>approvals only</i>)	Yes, date
*	BLAs only: is the product subject to official FDA lot release per 21 CFR 610.2 (approvals only)	Yes No
*	Public communications (approvals only)	
	Office of Executive Programs (OEP) liaison has been notified of action	Yes No 1/14/09
	• Press Office notified of action (by OEP)	🛛 Yes 🗌 No 1/14/09
	• Indicate what types (if any) of information dissemination are anticipated	 None HHS Press Release FDA Talk Paper CDER Q&As Other

 $^{^{2}}$ All questions in all sections pertain to the pending application, i.e., if the pending application is an NDA or BLA supplement, then the questions should be answered in relation to that supplement, not in relation to the original NDA or BLA. For example, if the application is a pending BLA supplement, then a new *RMS-BLA Product Information Sheet for TBP* must be completed.

*	Exclusivity	
	• Is approval of this application blocked by any type of exclusivity?	🖾 No 🗌 Yes
	• NDAs and BLAs: Is there existing orphan drug exclusivity for the "same" drug or biologic for the proposed indication(s)? <i>Refer to 21 CFR</i> 316.3(b)(13) for the definition of "same drug" for an orphan drug (i.e., active moiety). This definition is NOT the same as that used for NDA chemical classification.	No Yes If, yes, NDA/BLA # and date exclusivity expires:
	• (b)(2) NDAs only: Is there remaining 5-year exclusivity that would bar effective approval of a 505(b)(2) application)? (<i>Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.</i>)	☐ No ☐ Yes If yes, NDA # and date exclusivity expires:
	• (b)(2) NDAs only: Is there remaining 3-year exclusivity that would bar effective approval of a 505(b)(2) application? (<i>Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.</i>)	☐ No ☐ Yes If yes, NDA # and date exclusivity expires:
	• (b)(2) NDAs only: Is there remaining 6-month pediatric exclusivity that would bar effective approval of a 505(b)(2) application? (<i>Note that, even if exclusivity remains, the application may be tentatively approved if it is otherwise ready for approval.</i>)	☐ No ☐ Yes If yes, NDA # and date exclusivity expires:
	• NDAs only: Is this a single enantiomer that falls under the 10-year approval limitation of 505(u)? (<i>Note that, even if the 10-year approval limitation period has not expired, the application may be tentatively approved if it is otherwise ready for approval.</i>)	No Yes If yes, NDA # and date 10- year limitation expires:
*	Patent Information (NDAs only)	
	• Patent Information: Verify that form FDA-3542a was submitted for patents that claim the drug for which approval is sought. If the drug is an old antibiotic, skip the Patent Certification questions.	 Verified Not applicable because drug is an old antibiotic.
	• Patent Certification [505(b)(2) applications]: Verify that a certification was submitted for each patent for the listed drug(s) in the Orange Book and identify the type of certification submitted for each patent.	21 CFR 314.50(i)(1)(<i>i</i>)(A) ☐ Verified 21 CFR 314.50(i)(1) ☐ (ii) ☐ (iii)
	• [505(b)(2) applications] If the application includes a paragraph III certification, it cannot be approved until the date that the patent to which the certification pertains expires (but may be tentatively approved if it is otherwise ready for approval).	No paragraph III certification Date patent will expire
	• [505(b)(2) applications] For each paragraph IV certification, verify that the applicant notified the NDA holder and patent owner(s) of its certification that the patent(s) is invalid, unenforceable, or will not be infringed (review documentation of notification by applicant and documentation of receipt of notice by patent owner and NDA holder). <i>(If the application does not include any paragraph IV certifications, mark "N/A" and skip to the next section below</i> (Summary Reviews)).	 N/A (no paragraph IV certification) Verified

[505(b)(2) applications] For each paragraph IV certification, based on the questions below, determine whether a 30-month stay of approval is in effect due to patent infringement litigation.		
Answer the following questions for each paragraph IV certification:		
(1) Have 45 days passed since the patent owner's receipt of the applicant's notice of certification?	Yes	🗌 No
(Note: The date that the patent owner received the applicant's notice of certification can be determined by checking the application. The applicant is required to amend its 505(b)(2) application to include documentation of this date (e.g., copy of return receipt or letter from recipient acknowledging its receipt of the notice) (see 21 CFR 314.52(e))).		
If "Yes," skip to question (4) below. If "No," continue with question (2).		
(2) Has the patent owner (or NDA holder, if it is an exclusive patent licensee) submitted a written waiver of its right to file a legal action for patent infringement after receiving the applicant's notice of certification, as provided for by 21 CFR 314.107(f)(3)?	🗌 Yes	🗌 No
If " Yes ," there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip the rest of the patent questions.		
If "No," continue with question (3).		
(3) Has the patent owner, its representative, or the exclusive patent licensee filed a lawsuit for patent infringement against the applicant?	Yes	🗌 No
(Note: This can be determined by confirming whether the Division has received a written notice from the (b)(2) applicant (or the patent owner or its representative) stating that a legal action was filed within 45 days of receipt of its notice of certification. The applicant is required to notify the Division in writing whenever an action has been filed within this 45-day period (see 21 CFR 314.107(f)(2))).		
If "No," the patent owner (or NDA holder, if it is an exclusive patent licensee) has until the expiration of the 45-day period described in question (1) to waive its right to bring a patent infringement action or to bring such an action. After the 45-day period expires, continue with question (4) below.		
(4) Did the patent owner (or NDA holder, if it is an exclusive patent licensee) submit a written waiver of its right to file a legal action for patent infringement within the 45-day period described in question (1), as provided for by 21 CFR 314.107(f)(3)?	🗌 Yes	🗌 No
If "Yes," there is no stay of approval based on this certification. Analyze the next paragraph IV certification in the application, if any. If there are no other paragraph IV certifications, skip to the next section below (Summary Reviews).		
If "No," continue with question (5).		

	 (5) Did the patent owner, its representative, or the exclusive patent licensee bring suit against the (b)(2) applicant for patent infringement within 45 days of the patent owner's receipt of the applicant's notice of certification? (Note: This can be determined by confirming whether the Division has received a written notice from the (b)(2) applicant (or the patent owner or its representative) stating that a legal action was filed within 45 days of receipt of its notice of certification. The applicant is required to notify the Division in writing whenever an action has been filed within this 45-day period (see 21 CFR 314.107(f)(2)). If no written notice appears in the NDA file, confirm with the applicant whether a lawsuit was commenced within the 45-day period). If "No," there is no stay of approval based on this certification. Analyze the next paragraph IV certifications, skip to the next section below (Summary Reviews). If "Yes," a stay of approval may be in effect. To determine if a 30-month stay is in effect, consult with the OND ADRA and attach a summary of the response. 	☐ Yes ☐ No	
	CONTENTS OF ACTION PACKAGE		
*	Copy of this Action Package Checklist ³	January 29, 2009	
	Officer/Employee List		
*	List of officers/employees who participated in the decision to approve this application and consented to be identified on this list (<i>approvals only</i>)	Included	
	Documentation of consent/non-consent by officers/employees	Included	
	Documentation of consent/non-consent by officers/employees Action Letters	Included	
*		Action(s) and date(s) January 27, 2009	
*	Action Letters	Action(s) and date(s)	
*	Action Letters Copies of all action letters (including approval letter with final labeling)	Action(s) and date(s)	
	Action Letters Copies of all action letters (including approval letter with final labeling) Labeling	Action(s) and date(s)	
	Action Letters Copies of all action letters (including approval letter with final labeling) Labeling Package Insert (write submission/communication date at upper right of first page of PI) • Most recent division-proposed labeling (only if generated after latest applicant	Action(s) and date(s)	
	Action Letters Copies of all action letters (including approval letter with final labeling) Labeling Package Insert (write submission/communication date at upper right of first page of PI) • Most recent division-proposed labeling (only if generated after latest applicant submission of labeling) • Most recent submitted by applicant labeling (only if subsequent division labeling	Action(s) and date(s) January 27, 2009 Original 01/31/08 Annotated 02/15/08 PLR format10/31/08	
	Action Letters Copies of all action letters (including approval letter with final labeling) Labeling Package Insert (write submission/communication date at upper right of first page of PI) • Most recent division-proposed labeling (only if generated after latest applicant submission of labeling) • Most recent submitted by applicant labeling (only if subsequent division labeling does not show applicant version)	Action(s) and date(s) January 27, 2009 Original 01/31/08 Annotated 02/15/08	

³ Fill in blanks with dates of reviews, letters, etc. Version: 9/5/08

	• Most-recent division-proposed labeling (only if generated after latest applicant submission of labeling)		
	• Most recent submitted by applicant labeling (only if subsequent division labeling does not show applicant version)		
	Original applicant-proposed labeling		
	• Other relevant labeling (e.g., most recent 3 in class, class labeling), if applicable		
*	Labels (full color carton and immediate-container labels) (<i>write</i> submission/communication date at upper right of first page of each submission)		
	• Most-recent division proposal for (only if generated after latest applicant submission)		
	Most recent applicant-proposed labeling		
*	Labeling reviews (indicate dates of reviews and meetings)	 □ RPM ▷ DMEDP 12/31/08 ▷ DRISK 12/17/08 ▷ DDMAC 8/4/08 □ CSS ○ Other reviews SEALD 01/15/09 Maternal Health 01/15/09 	
*	 Proprietary Name Review(s) (<i>indicate date(s)</i>) Acceptability/non-acceptability letter(s) (<i>indicate date(s)</i>) 	December 15, 2008 Acceptable	
	Administrative / Regulatory Documents		
*	Administrative Reviews (e.g., RPM Filing Review ⁴ /Memo of Filing Meeting) (indicate date of each review)	Filing Meeting-06/12/08 Filing Review- 06/12/08	
*	NDAs only: Exclusivity Summary (signed by Division Director)	Included 1/27/09	
*	Application Integrity Policy (AIP) Status and Related Documents www fda.gov/ora/compliance ref/aip page html		
	Applicant in on the AIP	Yes No	
	 This application is on the AIP If yes, Center Director's Exception for Review memo (<i>indicate date</i>) If yes, OC clearance for approval (<i>indicate date of clearance</i> 	□ Yes No □ Yes No □ Not an AP action	
*	 This application is on the AIP If yes, Center Director's Exception for Review memo (indicate date) If yes, OC clearance for approval (indicate date of clearance communication) 	☐ Yes ⊠ No ☐ Not an AP action	
*	 This application is on the AIP If yes, Center Director's Exception for Review memo (<i>indicate date</i>) If yes, OC clearance for approval (<i>indicate date of clearance</i> 	☐ Yes ⊠ No	
	 This application is on the AIP If yes, Center Director's Exception for Review memo (<i>indicate date</i>) If yes, OC clearance for approval (<i>indicate date of clearance communication</i>) Pediatric Page (<i>approvals only, must be reviewed by PERC before finalized</i>) Debarment certification (original applications only): verified that qualifying language was not used in certification and that certifications from foreign applicants are cosigned by 	 ☐ Yes ⊠ No ☐ Not an AP action ☑ Included 01/28/09 ☑ Verified, statement is 	
*	 This application is on the AIP If yes, Center Director's Exception for Review memo (indicate date) If yes, OC clearance for approval (indicate date of clearance communication) Pediatric Page (approvals only, must be reviewed by PERC before finalized) Debarment certification (original applications only): verified that qualifying language was not used in certification and that certifications from foreign applicants are cosigned by U.S. agent (include certification) 	 ☐ Yes ⊠ No ☐ Not an AP action ☑ Included 01/28/09 ☑ Verified, statement is acceptable 	
*	 This application is on the AIP If yes, Center Director's Exception for Review memo (indicate date) If yes, OC clearance for approval (indicate date of clearance communication) Pediatric Page (approvals only, must be reviewed by PERC before finalized) Debarment certification (original applications only): verified that qualifying language was not used in certification and that certifications from foreign applicants are cosigned by U.S. agent (include certification) Postmarketing Requirement (PMR) Studies 	 ☐ Yes ⊠ No ☐ Not an AP action ☑ Included 01/28/09 ☑ Verified, statement is acceptable 	

⁴ Filing reviews for other disciplines should be filed behind the discipline tab. Version: 9/5/08

	• Outgoing Agency request for postmarketing commitments (<i>if located elsewhere in package, state where located</i>)		
	Incoming submission documenting commitment		
*	Outgoing communications (letters (except previous action letters), emails, faxes, telecons)		
*	Internal memoranda, telecons, etc.		
*	Minutes of Meetings		
	• PeRC (indicate date; approvals only)	Not applicable 01/14/09	
	• Pre-Approval Safety Conference (indicate date; approvals only)	Not applicable	
	Regulatory Briefing (indicate date)	🖾 No mtg	
	• Pre-NDA/BLA meeting (<i>indicate date</i>)	□ No mtg 12/04/07	
	• EOP2 meeting (<i>indicate date</i>)	□ No mtg 08/02/05	
	• Other (e.g., EOP2a, CMC pilot programs)	Tcon 12/18/08 Tcon 11/02/05 Type C CMC/Micro 12/07/06	
*	Advisory Committee Meeting(s)	No AC meeting	
	• Date(s) of Meeting(s)		
	• 48-hour alert or minutes, if available		
	Decisional and Summary Memos		
*	Office Director Decisional Memo (indicate date for each review)	🛛 None	
	Division Director Summary Review (indicate date for each review)	□ None 1/26/09	
	Cross-Discipline Team Leader Review (indicate date for each review)	⊠ None	
	Clinical Information ⁵		
*	Clinical Reviews		
	• Clinical Team Leader Review(s) (<i>indicate date for each review</i>)	See Director Review	
	Clinical review(s) (indicate date for each review)	January 26, 2009	
	• Social scientist review(s) (if OTC drug) (indicate date for each review)	None None	
*	Safety update review(s) (indicate location/date if incorporated into another review)	See Clinical Review 01/26/09 Pages 67 and 68	
*	Financial Disclosure reviews(s) or location/date if addressed in another review		
	OR If no financial disclosure information was required, review/memo explaining why not		
*	Clinical reviews from other clinical areas/divisions/Centers (indicate date of each review)	None None	
*	Controlled Substance Staff review(s) and Scheduling Recommendation (<i>indicate date of each review</i>)	⊠ Not needed	
*	 Risk Management Review(s) and recommendations (including those by OSE and CSS) (indicate date of each review and indicate location/date if incorporated into another review) REMS Memo (indicate date) REMS Document and Supporting Statement (indicate date(s) of submission(s)) 	None None	

⁵ Filing reviews should be filed with the discipline reviews. Version: 9/5/08

*	DSI Clinical Inspection Review Summary(ies) (include copies of DSI letters to investigators)	None requested 10/03/08	
	Clinical Microbiology None		
*	Clinical Microbiology Team Leader Review(s) (indicate date for each review)	None None	
	Clinical Microbiology Review(s) (indicate date for each review)	None None	
	Biostatistics None		
*	Statistical Division Director Review(s) (indicate date for each review)	🛛 None	
	Statistical Team Leader Review(s) (indicate date for each review)	🛛 None	
	Statistical Review(s) (indicate date for each review)	□ None 11/26/08	
	Clinical Pharmacology None		
*	Clinical Pharmacology Division Director Review(s) (indicate date for each review)	None None	
	Clinical Pharmacology Team Leader Review(s) (indicate date for each review)	None None	
	Clinical Pharmacology review(s) (indicate date for each review)	□ None 01/21/09	
*	DSI Clinical Pharmacology Inspection Review Summary (include copies of DSI letters)	None None	
	Nonclinical None		
*	Pharmacology/Toxicology Discipline Reviews		
	• ADP/T Review(s) (indicate date for each review)	None None	
	• Supervisory Review(s) (indicate date for each review)	None None	
	 Pharm/tox review(s), including referenced IND reviews (indicate date for each review) 	None 11/26/08 and 01/21/09	
*	Review(s) by other disciplines/divisions/Centers requested by P/T reviewer (<i>indicate date for each review</i>)	🔀 None	
*	Statistical review(s) of carcinogenicity studies (indicate date for each review)	No carc	
*	ECAC/CAC report/memo of meeting	None Included in P/T review, page	
*	DSI Nonclinical Inspection Review Summary (include copies of DSI letters)	None requested	
	CMC/Quality None		
*	CMC/Quality Discipline Reviews		
	ONDQA/OBP Division Director Review(s) (indicate date for each review)	None None	
	Branch Chief/Team Leader Review(s) (indicate date for each review)	None None	
	• CMC/product quality review(s) (<i>indicate date for each review</i>)	None 01/26/09	
	• BLAs only: Facility information review(s) (indicate dates)	None None	
*	 Microbiology Reviews NDAs: Microbiology reviews (sterility & pyrogenicity) (<i>indicate date of each review</i>) 	12/02/08	
	• BLAs: Sterility assurance, product quality microbiology (<i>indicate date of each review</i>)	Not needed	
*	Reviews by other disciplines/divisions/Centers requested by CMC/quality reviewer (<i>indicate date of each review</i>)	None	
*	Environmental Assessment (check one) (original and supplemental applications)	See CMC review Page 54 (01/26/09)	

	Categorical Exclusion (indicate review date)(all original applications and all efficacy supplements that could increase the patient population)	
	Review & FONSI (indicate date of review)	
	Review & Environmental Impact Statement (indicate date of each review)	See CMC Review 01/26/09 Page 54
*	NDAs: Methods Validation	 Completed See CMC Review Page 50 Requested Not yet requested Not needed
*	Facilities Review/Inspection	
	• NDAs: Facilities inspections (include EER printout) (date completed must be within 2 years of action date)	Date completed: 01/26/09 See CMC Review Page 7 Acceptable Withhold recommendation
	• BLAs: • TBP-EER	Date completed: Acceptable Withhold recommendation
	• Compliance Status Check (approvals only, both original and all supplemental applications except CBEs) (<i>date completed must be within 60 days prior to AP</i>)	Date completed: Requested Accepted Hold

Appendix A to Action Package Checklist

An NDA or NDA supplemental application is likely to be a 505(b)(2) application if:

- (1) It relies on published literature to meet any of the approval requirements, and the applicant does not have a written right of reference to the underlying data. If published literature is cited in the NDA but is not necessary for approval, the inclusion of such literature will not, in itself, make the application a 505(b)(2) application.
- (2) Or it relies for approval on the Agency's previous findings of safety and efficacy for a listed drug product and the applicant does not own or have right to reference the data supporting that approval.
- (3) **Or** it relies on what is "generally known" or "scientifically accepted" about a class of products to support the safety or effectiveness of the particular drug for which the applicant is seeking approval. (Note, however, that this does not mean *any* reference to general information or knowledge (e.g., about disease etiology, support for particular endpoints, methods of analysis) causes the application to be a 505(b)(2) application.)

Types of products for which 505(b)(2) applications are likely to be submitted include: fixed-dose combination drug products (e.g., heart drug and diuretic (hydrochlorothiazide) combinations); OTC monograph deviations(see 21 CFR 330.11); new dosage forms; new indications; and, new salts.

An efficacy supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2).

An efficacy supplement is a 505(b)(1) supplement if the supplement contains all of the information needed to support the approval of the change proposed in the supplement. For example, if the supplemental application is for a new indication, the supplement is a 505(b)(1) if:

- (1) The applicant has conducted its own studies to support the new indication (or otherwise owns or has right of reference to the data/studies).
- (2) And no additional information beyond what is included in the supplement or was embodied in the finding of safety and effectiveness for the original application or previously approved supplements is needed to support the change. For example, this would likely be the case with respect to safety considerations if the dose(s) was/were the same as (or lower than) the original application.
- (3) And all other "criteria" are met (e.g., the applicant owns or has right of reference to the data relied upon for approval of the supplement, the application does not rely for approval on published literature based on data to which the applicant does not have a right of reference).

An efficacy supplement is a 505(b)(2) supplement if:

- (1) Approval of the change proposed in the supplemental application would require data beyond that needed to support our previous finding of safety and efficacy in the approval of the original application (or earlier supplement), and the applicant has not conducted all of its own studies for approval of the change, or obtained a right to reference studies it does not own. For example, if the change were for a new indication AND a higher dose, we would likely require clinical efficacy data and preclinical safety data to approve the higher dose. If the applicant provided the effectiveness data, but had to rely on a different listed drug, or a new aspect of a previously cited listed drug, to support the safety of the new dose, the supplement would be a 505(b)(2).
- (2) **Or** the applicant relies for approval of the supplement on published literature that is based on data that the applicant does not own or have a right to reference. If published literature is cited in the supplement but is not necessary for approval, the inclusion of such literature will not, in itself, make the supplement a 505(b)(2) supplement.
- (3) Or the applicant is relying upon any data they do not own or to which they do not have right of reference.

If you have questions about whether an application is a 505(b)(1) or 505(b)(2) application, consult with your ODE's ADRA.

/s/ Jeannie Roule

1/29/2009 03:19:22 PM

NDA 22-204

1

1

1

INFORMATION REQUEST LETTER

(b) (4)

Watson Laboratories, Inc. Attention: Lawrence Ventura, D.V.M., M.B.A. Associate Director, Regulatory Liaison 577 Chipeta Way Salt Lake City, UT 84108

Dear Dr. Ventura:

Please refer to your March 27, 2008, new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Gelnique (oxybutynin chloride) Gel.

We are reviewing your current Gelnique label and carton and have the following comments and information requests. We request a prompt written response in order to continue our evaluation of your NDA.

1. All Labels and Labeling

The established name is not consistently presented throughout the labels and labeling. Ensure that the established name is consistently presented throughout all labels and labeling. The recommended presentation is as follows:

PROPRIETARY NAME (oxybutynin chloride) Gel 10%

2. Container Label and Carton Labeling

a. The proprietary name "Gelnique" has the following presentation: the first three letters

3. Carton Labeling

4. Insert Labeling

Section 17.1. states: "It is recommended that application sites be covered if close skin-toskin contact is anticipated." Please specify what are considered to be appropriate and inappropriate coverings.

If you have any questions, call Jeannie Roule, Regulatory Health Project Manager, at 301-796-3993.

Sincerely,

Jennifer Mercier Chief, Project Management Staff Division of Reproduction and Urologic Products Office of Drug Evaluation III Center for Drug Evaluation and Research (b) (4)

(b) (4)

/s/ ------Jennifer L. Mercier 1/6/2009 03:59:21 PM



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration Rockville, MD 20857

NDA 22-204

INFORMATION REQUEST LETTER

Watson Laboratories, Inc. Attention: Lawrence Ventura, D.V.M., M.B.A. Associate Director, Regulatory Liaison Proprietary Products Registration 577 Chipeta Way Salt Lake City, UT 84108

Dear Dr. Ventura:

Please refer to your March 26, 2008, new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Oxybutynin Chloride Topical Gel.

We also refer to your submission dated September 11, 2008.

We have completed the review of your proposed pediatric development plan in the deferred population (children ages 5 to 17 years) for Oxybutynin Chloride Topical Gel (OTG). We have the following comments and information requests.

- Your proposed pharmacokinetic study in 40 children does not adequately assess the safety and effectiveness of OTG in the pediatric population.
- A clinical safety and efficacy trial should be conducted in the target pediatric population.

We request that you submit your revised pediatric development plan for the deferred population as soon as possible so that it can be reviewed and determined whether deferral under the Pediatric Research Equity Act (PREA) is acceptable. The Division's approval of this pediatric plan is necessary prior to the approval of your application for the use of OTG in the adult population.

If you have any questions, call Jeannie Roule, Regulatory Health Project Manager, at 301-796-3993.

Sincerely,

George Benson, M.D. Deputy Director Division of Reproductive and Urologic Products Office of Drug Evaluation III Center for Drug Evaluation and Research



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration Rockville, MD 20857

NDA 22-204

INFORMATION REQUEST LETTER

Watson Laboratories, Inc. Attention: Lawrence Ventura, D.V.M., M.B.A. Associate Director, Regulatory Liaison Regulatory Affairs Watson Laboratories, Inc.-Utah 577 Chipeta Way Salt Lake City, UT 84108

Dear Dr. Ventura:

Please refer to your March 26, 2008, new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Oxybutinin Chloride Topical Gel.

We are reviewing the Microbiology section of your submission and have the following comments and information requests regarding the microbial limits testing on Oxybutynin Chloride Topical Gel. We request a prompt written response in order to continue our evaluation of your NDA.

Please provide the following information:

- The microbial limits release specification and microbial limits stability test schedule for the drug product.
- The test protocol and validation data for microbial limits testing

Please note that the microbial limits testing may be relaxed depending upon the level of microbial control of raw materials, the production environment, in process control parameters (e.g. heat, drying, washing) which may affect product quality microbiology, and product history. See decision tree #8 of the "International Conference on Harmonization" (ICH) Q6A Specifications : Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products : Chemical Substances" for additional information.

If you have any questions, call Jeannie Roule, Regulatory Health Project Manager, at (301) 796-3993.

Sincerely,

(See appended electronic signature page)

Jennifer Mercier Chief, Project Management Staff Division of Reproductive and Urologic Products Office of Drug Evaluation III Center for Drug Evaluation and Research

/s/ Jennifer L. Mercier 9/4/2008 01:45:14 PM



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration Rockville, MD 20857

FILING COMMUNICATION

NDA 22-204

Watson Laboratories, Inc. Attention: Kevin Barber Executive Director, Regulatory Affairs 577 Chipeta Way Salt Lake City, UT 84108

Dear Mr. Barber:

Please refer to your new drug application (NDA) dated March 26, 2008, received March 27, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act, for oxybutynin chloride topical gel, 100mg/gram.

We have completed our filing review and have determined that your application is sufficiently complete to permit a substantive review. Therefore, in accordance with 21 CFR 314.101(a), this application is considered filed 60 days after the date we received your application. The review classification for this application is **Standard**. Therefore, the user fee goal date is January 27, 2009.

We are providing these comments to give you preliminary notice of <u>potential</u> review issues. Our filing review is only a preliminary evaluation of the application and is not indicative of deficiencies that may be identified during our review. Issues may be added, deleted, expanded upon, or modified as we review the application.

Clinical

- 1. Skin safety, especially skin sensitization, will be a review issue.
- 2. The changes from baseline in the Incontinence Impact Questionnaire total score and subscales and in the King's Health Questionnaire domain scores are considered exploratory endpoints. We currently do not anticipate including data from these questionnaires in labeling.
- 3. Provide case narratives for all subjects/patients who discontinued prematurely due to an adverse event.
- 4. For Study OG05009, provide summaries for the following laboratory outliers:
 - AST \geq 3X ULN and \geq 5X ULN
 - ALT \geq 3X ULN and \geq 5X ULN

- Total bilirubin $\geq 2X$ ULN
- Creatinine \geq 2X ULN
- These summaries should be provided for the placebo and treatment groups in the double-blind phase, and for the treatment group with < 12 weeks OTG exposure and the treatment group with \geq 12 weeks of exposure in the double-blind and open-label phases.
- 5. Define what changes in laboratory parameters are considered as "clinically significant" in Table 12-10 (page 88) of the Study Report for OG05009.
- 6. For Study OG05009, provide summaries of clinically significant changes in vital signs for the absolute change from baseline (e.g., systolic BP change ≥ 20 mmHg) separately from those exceeding a pre-defined value (e.g., systolic BP ≥ 180 mmHg).
- 7. We acknowledge your plans to fulfill the PREA requirements and will determine the acceptability of your proposed plans prior to the PDUFA date of January 27, 2009.

Chemistry

- 8. Update the NDC number on the container labels, and include the NDC number on the Package Insert in the How Supplied section and in the DLDE section of the SPL label.
- 9. Provide color mock-ups for the carton and immediate container labels, including any logos, to allow full review of these labels.

Pharmacology/Toxicology

- 10. Provide reviewable toxicology data for the four leachable substances found in the drug product (b) (4)) justifying their safe use under chronic dermal exposure conditions.
- 11. Provide structure activity analyses for the metabolite PCGA and the (b) (4) for review.

Respond only to the above requests for additional information. While we anticipate that any response submitted in a timely manner will be reviewed during this review cycle, such review decisions will be made on a case-by-case basis.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We acknowledge receipt of your waiver request for conducting pediatric studies in children from birth through 4 years of age. We also acknowledge receipt of your request for a deferral of pediatric studies in children ages 5 - 17 years old for this application. We will forward this request to the Pediatric Review Committee.

NDA 22-204 Page 3

\

If you have any questions, call Celia R. Hayes, MPH, RD Regulatory Project Manager, at (301) 796-4154.

Sincerely,

{See appended electronic signature page}

George Benson, M.D. Deputy Director Division of Reproductive and Urologic Products Office of Drug Evaluation III Center for Drug Evaluation and Research

/s/

George Benson 6/6/2008 11:55:54 AM



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration Rockville, MD 20857

NDA 22-204

NDA ACKNOWLEDGMENT

Watson Laboratories, Inc. Attention: Kevin Barber, Ph.D., RAC, P.M.P. Executive Director, Regulatory Affairs 577 Chipeta Way Salt Lake City, Utah 84108

Dear Dr. Barber:

We have received your new drug application (NDA) submitted under section 505(b of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Oxybutynin Chloride Topical Gel

Date of Application: March 26, 2008

Date of Receipt: March 27, 2008

Our Reference Number: NDA 22-204

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application May 26, 2008, in accordance with 21 CFR 314.101(a).

If you have not already done so, promptly submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at <u>http://www.fda.gov/oc/datacouncil/spl.html</u>. Failure to submit the content of labeling in SPL format may result in a refusal-to-file action under 21 CFR 314.101(d)(3). The content of labeling must be in the Prescribing Information (physician labeling rule) format.

The NDA number provided above must be cited at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

Food and Drug Administration Center for Drug Evaluation and Research Division of Reproductive and Urologic Products 5901-B Ammendale Road Beltsville, MD 20705-1266 NDA 22-204 Page 2

All regulatory documents submitted in paper should be three-hole punched on the left side of the page and bound. The left margin should be at least three-fourths of an inch to assure text is not obscured in the fastened area. Standard paper size (8-1/2 by 11 inches) should be used; however, it may occasionally be necessary to use individual pages larger than standard paper size. Non-standard, large pages should be folded and mounted to allow the page to be opened for review without disassembling the jacket and refolded without damage when the volume is shelved. Shipping unbound documents may result in the loss of portions of the submission or an unnecessary delay in processing which could have an adverse impact on the review of the submission. For additional information, please see http://www.fda.gov/cder/ddms/binders.htm.

If you have any questions, call Celia R. Hayes, MPH, RD, Regulatory Project Manager, at (301) 796-4154.

Sincerely,

{See appended electronic signature page}

Jennifer Mercier Chief, Project Management Staff Division of Reproductive and Urologic Products Office of Drug Evaluation III Center for Drug Evaluation and Research

/s/

Jennifer L. Mercier 4/15/2008 10:00:24 AM